The comparative in vitro activities of two new oxazolidinone antimicrobial agents, U-100592 and U-100766, against 180 isolates of enterococci representing several resistance profiles were examined by using an agar dilution technique. The two oxazolidinones inhibited all isolates, including strains resistant to vancomycin, ampicillin, and minocycline, at concentrations of between 1 and 4 g/ml.
Antibiotic-resistant enterococci are becoming increasingly important pathogens in the clinical setting (15) . The recent emergence of glycopeptide resistance in this genus further complicates the situation (1), rendering some isolates resistant to virtually all available antibiotics. As a result, there is a pressing need for the development of novel agents with activity against multiple-drug-resistant enterococci.
The oxazolidinones are a group of synthetic antibacterial compounds unrelated to other known antimicrobial agents (6, 7) . Studies with earlier agents of this class demonstrated an inhibition of protein synthesis (6, 7) , without effect on DNA or RNA synthesis (7) . A series of new analogs with enhanced potency against gram-positive organisms has now been described (2, 4, 13) . The present study examines the in vitro activities of two of these newer oxazolidinones, U-100592 and U-100766 (4), against a broad range of enterococcal isolates, including strains resistant to multiple antibiotics. The chemical structures of these compounds are shown in Fig. 1 .
(This work was presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 1995 [9] .)
The bacterial strains used in this study had been referred to our collection from numerous sources over several years. These strains were collected in the northeast United States, except for class A glycopeptide-resistant Enterococcus faecalis, which was collected in Spain (5) . Organisms were identified on the basis of biochemical reactions (API 20 Strep; bioMérieux Vitek, Inc., Hazelwood, Mo.) and physical properties such as color and motility (10) . Appropriateness of assignment to phenotypic glycopeptide resistance classes A or B was checked by genotyping about half (58%) of the vancomycin-resistant E. faecalis and E. faecium with DNA probes for the vanA gene of E. faecium 228 (12) and for the class B ligase gene (vanB2) of E. faecalis SF300 (11) .
In vitro activities of the oxazolidinones and comparative antibiotics were determined by agar dilution on Mueller-Hinton II agar (BBL Microbiology Systems, Cockeysville, Md.) according to recommended procedures (16) . Inocula of approximately 10 4 CFU per spot were applied to plates, which were incubated 20 h at 35ЊC in room air. Several strains were chosen for inclusion in this study on the basis of high-level resistance to aminoglycosides, which was determined on plates containing streptomycin or gentamicin incorporated into brain-heart infusion agar at 2,000 or 500 g/ml, respectively, inoculated with 10 l of a 0.5 McFarland standard-equivalent suspension of the organisms, and held for 48 h according to the recommendations of the National Committee for Clinical Laboratory Standards (16) . MICs were subsequently determined by the standard method on Mueller-Hinton agar with replicator inoculation. Bactericidal activities of the two oxazolidinones were examined by time-kill methods against four strains, all of which were inhibited by both drugs at 1 g/ml. Tests were carried out in 20-ml volumes of brain-heart infusion broth containing the antimicrobial agents at 8 g/ml and the inocula at 10 7 CFU/ml, with incubation at 35ЊC and sampling at 0, 4, and 24 h.
The oxazolidinones U-100592 and U-100766 were provided by The Upjohn Company, Kalamazoo, Mich. Vancomycin was a gift of Eli Lilly and Co., Indianapolis, Ind., and teicoplanin was a gift of the Marion Merrell Dow Research Institute, Marion Merrell Dow, Inc., Cincinnati, Ohio. Ampicillin, minocycline, and streptomycin were purchased from Sigma The oxazolidinones inhibited all isolates of enterococci at concentrations of between 1 and 4 g/ml (Table 1) . On the basis of comparisons of the MICs at which 50% of the isolates are inhibited (MIC 50 s) and the MIC 90 s, the activity of U-100592 was equal to or twofold greater than that of U-100766. A strain-by-strain comparison revealed that U-100592 was twice as potent as U-100766 against approximately 50% of the strains and was fourfold more active against four strains (all vancomycin-resistant E. faecalis and E. faecium). U-100766 was twice as active as U-100592 against only three strains, all of which were vancomycin-resistant E. faecium. At eight times the MIC, each of the oxazolidinones was bacteriostatic against two isolates of E. faecalis and two isolates of E. faecium at the 4-h sampling point. At the 24-h sampling point, a killing rate of Ͻ1 log 10 CFU/ml was noted with each agent against two strains, and a killing rate of Ͻ2 log 10 CFU/ml was noted against another. For one strain of E. faecium, U-100592 and U-100766 reduced viable bacteria by 3.11 log 10 CFU/ml and 2.65 log 10 CFU/ml, respectively.
One-third of the organisms were resistant to minocycline (MIC Ն 16 g/ml). Of the class A glycopeptide-resistant strains of E. faecium, 74% were highly resistant to ampicillin (MIC Ն 128 g/ml). For the 18 strains of E. faecium and 21 strains of E. faecalis included in this study on the basis of high-level resistance to gentamicin as determined by the National Committee for Clinical Laboratory Standards agar screening method (16) , the MICs of gentamicin for 32 strains was Ͼ2,000 g/ml and all were inhibited by gentamicin at concentrations of Ͼ1,000 g/ml when replicator inoculation was performed on Mueller-Hinton II agar. Strains for which the MICs of gentamicin were Ͼ500 g/ml by routine testing were infrequently susceptible to streptomycin at concentrations of Յ2,000 g/ml; this pattern occurred with 8 and 18% of E. faecium and E. faecalis strains, respectively. Of the other species studied here, high-level resistance to gentamicin was seen only with one isolate of E. gallinarum.
Neither of the oxazolidinones inhibited Escherichia coli ATCC 25922 at the concentrations tested (MIC Ͼ 128 g/ml). The MIC of U-100592 for Staphylococcus aureus ATCC 29213 was 2 g/ml in each of six determinations. MICs of U-100766 for the latter control strain were 2 g/ml in three trials and 4 g/ml on three occasions. The activities of ampicillin, vancomycin, and minocycline fell within the expected ranges (17) .
Despite the fact that the organisms examined in this study were generally included because of selected resistance characteristics and thus do not represent a random sample of current clinical isolates, the results we obtained, showing that U-100592 and U-100766 at concentrations of between 1 and 4 g/ml inhibited all strains, are consistent with those reported by other groups (3, 14, 18) . Although killing against one strain of E. faecium was achieved, as noted with earlier oxazolidinone agents the activity of these new compounds against enterococci appears to be primarily bacteriostatic (3, 6, 7, 18) . Nevertheless, at the present time there are few alternative antimicrobial agents in advanced stages of development with activity against current isolates of glycopeptide-and ␤-lactam-resistant enterococci and none of these provides reliable bactericidal activity either (5, 8, 15) . If pharmacokinetic characteristics and safety profiles of these compounds prove to be favorable, the oxazolidinones U-100592 and U-100766 could prove to be useful in the treatment of infections due to multiple-drug-resistant enterococci.
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